Psychiatric News (11/6) reports, “The Food and Drug Administration’s decision to approve brexpiprazole (Rexulti) for the treatment of agitation related to Alzheimer’s disease in May was met with a mixed response.” However, “JAMA Neurology published the results of a key phase 3 clinical trial used in the FDA’s decision.” The study found that after 12 weeks, participants’ average Cohen-Mansfield Agitation Inventory (CMAI) scores “dropped by 22.6 points in the combined brexpiprazole groups and 17.3 points in the placebo group, which was a statistically significant difference.”
Related Links:
— “Clinical Trial Supports Use of Brexpiprazole for Alzheimer’s Agitation, Study Suggests , Psychiatric News, November 6, 2023